Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.15
$1.15
$0.98
$1.89
$35.95M-0.6865,328 shs10,269 shs
DarioHealth Corp. stock logo
DRIO
DarioHealth
$1.45
+9.8%
$1.64
$0.68
$4.58
$42.69M1.67136,926 shs165,547 shs
Soliton, Inc. stock logo
SOLY
Soliton
$22.58
$21.55
$7.40
$22.60
$487.66M0.19347,827 shsN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
$3.86
+3.2%
$3.89
$1.03
$5.07
$115.72M2.44185,676 shs41,466 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
0.00%-1.71%-2.54%-10.16%-17.86%
DarioHealth Corp. stock logo
DRIO
DarioHealth
+9.85%+22.88%0.00%-30.95%-57.97%
Soliton, Inc. stock logo
SOLY
Soliton
0.00%0.00%0.00%0.00%0.00%
Neuronetics, Inc. stock logo
STIM
Neuronetics
+3.21%-4.46%-8.75%+11.88%+73.87%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.8061 of 5 stars
3.02.00.04.40.60.00.6
DarioHealth Corp. stock logo
DRIO
DarioHealth
1.9144 of 5 stars
3.52.00.00.01.80.81.3
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.2498 of 5 stars
3.33.00.00.00.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50117.39% Upside
DarioHealth Corp. stock logo
DRIO
DarioHealth
3.00
Buy$5.37270.11% Upside
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
2.50
Moderate Buy$8.00107.25% Upside

Current Analyst Ratings

Latest DRIO, STIM, SOLY, and CODX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
DarioHealth Corp. stock logo
DRIO
DarioHealth
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
3/26/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
3/6/2024
Neuronetics, Inc. stock logo
STIM
Neuronetics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.00
(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.28N/AN/A$2.81 per share0.41
DarioHealth Corp. stock logo
DRIO
DarioHealth
$20.35M2.10N/AN/A$2.14 per share0.68
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/A$1.46 per shareN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
$71.35M1.62N/AN/A$1.18 per share3.27

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Estimated)
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$59.43M-$1.03N/AN/AN/A-165.96%-48.84%-31.56%5/9/2024 (Estimated)
Soliton, Inc. stock logo
SOLY
Soliton
-$14.54M-$1.01N/AN/AN/AN/A-71.85%-62.92%N/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/14/2024 (Estimated)

Latest DRIO, STIM, SOLY, and CODX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$0.54-$0.41+$0.13-$0.41$3.57 million$3.62 million
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/5/202412/31/2023
Neuronetics, Inc. stock logo
STIM
Neuronetics
-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
N/AN/AN/AN/AN/A
Soliton, Inc. stock logo
SOLY
Soliton
N/AN/AN/AN/AN/A
Neuronetics, Inc. stock logo
STIM
Neuronetics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
DarioHealth Corp. stock logo
DRIO
DarioHealth
0.42
3.79
3.38
Soliton, Inc. stock logo
SOLY
Soliton
N/A
5.47
5.37
Neuronetics, Inc. stock logo
STIM
Neuronetics
1.73
4.73
4.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
DarioHealth Corp. stock logo
DRIO
DarioHealth
33.39%
Soliton, Inc. stock logo
SOLY
Soliton
35.11%
Neuronetics, Inc. stock logo
STIM
Neuronetics
53.59%

Insider Ownership

CompanyInsider Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
DarioHealth Corp. stock logo
DRIO
DarioHealth
10.10%
Soliton, Inc. stock logo
SOLY
Soliton
12.00%
Neuronetics, Inc. stock logo
STIM
Neuronetics
9.80%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
DarioHealth Corp. stock logo
DRIO
DarioHealth
27629.44 million26.47 millionOptionable
Soliton, Inc. stock logo
SOLY
Soliton
1421.60 million19.01 millionNot Optionable
Neuronetics, Inc. stock logo
STIM
Neuronetics
20329.98 million27.04 millionOptionable

DRIO, STIM, SOLY, and CODX Headlines

SourceHeadline
Neuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference CallNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Call
globenewswire.com - April 23 at 4:30 PM
Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%Short Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%
marketbeat.com - April 12 at 3:58 PM
New Study Offers Hope for Depression Patients Undergoing TMS TherapyNew Study Offers Hope for Depression Patients Undergoing TMS Therapy
msn.com - April 12 at 1:57 AM
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vital
globenewswire.com - April 10 at 8:31 AM
Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)Kent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)
marketbeat.com - April 6 at 7:36 PM
Neuronetics Stock (NASDAQ:STIM), Quotes and News SummaryNeuronetics Stock (NASDAQ:STIM), Quotes and News Summary
benzinga.com - April 5 at 5:38 AM
Neuronetics (STIM) FDA-Cleared NeuroStar to Aid in DepressionNeuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
zacks.com - April 1 at 11:56 AM
Neuronetics Bolsters Talent Pool with Strategic Stock Incentives for New HiresNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hires
msn.com - April 1 at 1:05 AM
Neurostar cleared for use in adolescent depressionNeurostar cleared for use in adolescent depression
bioworld.com - March 29 at 12:15 AM
FDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatmentFDA grants clearance to TMS device, NeuroStar as adjunct to first line depression treatment
medicaldialogues.in - March 29 at 12:15 AM
FDA Clears NeuroStars TMS Therapy for Adolescents with Major Depressive DisorderFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disorder
msn.com - March 29 at 12:15 AM
Neuronetics, Inc. (NASDAQ:STIM) Short Interest UpdateNeuronetics, Inc. (NASDAQ:STIM) Short Interest Update
marketbeat.com - March 28 at 11:57 AM
Neuronetics wins FDA clearance for device to treat adolescents with depressionNeuronetics wins FDA clearance for device to treat adolescents with depression
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 27 at 4:43 PM
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com - March 27 at 4:30 PM
Buy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD MarketBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Market
markets.businessinsider.com - March 27 at 6:41 AM
Neuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depressionNeuronetics’ magnetic stimulation cleared as first-line add-on therapy for adolescents with severe depression
fiercebiotech.com - March 27 at 6:41 AM
Neuronetics (STIM) "Market Perform" Rating Reiterated at William BlairNeuronetics' (STIM) "Market Perform" Rating Reiterated at William Blair
marketbeat.com - March 26 at 3:29 PM
TMS Device NeuroStar Cleared as Add-On Treatment for Adolescent DepressionTMS Device NeuroStar Cleared as Add-On Treatment for Adolescent Depression
empr.com - March 26 at 3:49 AM
Neuronetics’s NeuroStar wins FDA clearance for adolescents with depressionNeuronetics’s NeuroStar wins FDA clearance for adolescents with depression
msn.com - March 25 at 10:48 PM
Neuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with DepressionNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depression
finanznachrichten.de - March 25 at 12:07 PM
Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21Neuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21
marketwatch.com - March 25 at 12:07 PM
Neuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New IndicationNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indication
markets.businessinsider.com - March 25 at 12:07 PM
FDA clears Neuronetics’ neurostim for adolescents with depressionFDA clears Neuronetics’ neurostim for adolescents with depression
massdevice.com - March 25 at 12:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
DarioHealth logo

DarioHealth

NASDAQ:DRIO
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Soliton logo

Soliton

NASDAQ:SOLY
Soliton, Inc. is a medical development company, which engages in the development of healthcare technological devices for medical and cosmetic treatments. Its technology platform include Rapid Acoustic Pulse, a device uses rapid pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. The firm is also in the pre-revenue stage with its first products being developed for the removal of tattoos and the reduction of cellulite. The company was founded by Walter V. Klemp and Christopher Capelli on March 27, 2012 and is headquartered in Houston, TX.
Neuronetics logo

Neuronetics

NASDAQ:STIM
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.